Advertisement
Singapore markets closed

  • Straits Times Index

    3,455.94
    +14.17 (+0.41%)
     

  • S&P 500

    5,519.18
    +82.74 (+1.52%)
     

  • Dow

    40,861.00
    +117.67 (+0.29%)
     

  • Nasdaq

    17,550.78
    +403.37 (+2.35%)
     

  • Bitcoin USD

    66,293.41
    +266.83 (+0.40%)
     

  • CMC Crypto 200

    1,355.52
    +5.41 (+0.40%)
     

  • FTSE 100

    8,354.40
    +79.99 (+0.97%)
     

  • Gold

    2,467.30
    +15.40 (+0.63%)
     

  • Crude Oil

    76.63
    +1.90 (+2.54%)
     

  • 10-Yr Bond

    4.1010
    -0.0420 (-1.01%)
     

  • Nikkei

    39,101.82
    +575.87 (+1.49%)
     

  • Hang Seng

    17,344.60
    +341.69 (+2.01%)
     

  • FTSE Bursa Malaysia

    1,625.57
    +13.63 (+0.85%)
     

  • Jakarta Composite Index

    7,255.76
    +13.90 (+0.19%)
     

  • PSE Index

    6,619.09
    +12.73 (+0.19%)
     

Novo Nordisk expects US, EU and China decision on expanded Wegovy label in 2024

Reuters

COPENHAGEN, Jan 31 (Reuters) - Novo Nordisk said on Wednesday it expects U.S. regulators to decide by June on an expanded label indication for its anti-obesity drug Wegovy to include the heart benefits identified in a late-stage study called SELECT.

The company also expects Chinese and European Union regulators to decide on an expanded label in the second half of the year, the company's head of development, Martin Holst Lange, told analysts on a call.

(Reporting by Jacob Gronholt-Pedersen, Editing by Louise Heavens)